Regulatory approval
Published by the Health Service Executive.
The Republic of Ireland's Health Service Executive (HSE) has approved pembrolizumab in combination with pemetrexed and cisplatin for reimbursement as a treatment option for the first-line treatment of adult patients with metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have no EGFR or ALK positive mutations.
This is written in the approval document as:
Pembrolizumab is indicated in combination with PEMEtrexed and CISplatin for the first-line treatment of metastatic non-squamous NSCLC in adults whose tumors have no EGFR or ALK positive mutations
Citation
Pembrolizumab, PEMEtrexed and CISplatin Therapy, 2022, version number 4, NCCP National SACT Regimen, NCCP, viewed 04/04/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/569.pdfTherapeutic response
Precision oncology relationships for therapeutic response derived from this regulatory approval.| Type | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| Sensitivity (+) | Wild type ALK, Wild type EGFR | Non-Small Cell Lung Cancer | Cisplatin, Pembrolizumab, Pemetrexed |